AZD4954

Phase 1Small molecule

AstraZeneca

AZD4954 is one of 5 small molecule programs targeting Dyslipidemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DyslipidemiaRecruiting

DyslipidemiaPhase 1

Recruiting

Competition

Competitive Landscape

5 competitors in Dyslipidemia

#DrugCompanyPhaseTrials

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

4 2

Xuezhikang

Luye Pharma Group Ltd.

Phase 3

3 3

HRS-5632

FFujian Shengdi Pharmaceutical Co., Ltd.

AZD4954

1 5

Pueraria Lobata

JJiangxi University of Traditional Chinese Medicine

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Dyslipidemia

NCT06980428

Clinical

Trials by Indication[1]

Dyslipidemia1 trial

A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4954 Following Single and Multiple Ascending Dose Administration to Healthy Participants With or Without Elevated Lp(a) Levels, and Participants With Dyslipidemia

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT06980428·136 enrolled

Unspecified1 trial

An Open-label Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults.

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT07513571·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AZD4954. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD4954 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD4954. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AstraZeneca

AZD4954

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Dyslipidemia1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News